Payment overview · 2025
General Payments
$574.41
27 reported records · 10 companies
Healthcare provider profile · identity verified
Martha R Wafer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BOSSIER CITY, LA · NPI 1619179421
Verified facts
What the public records show
CMS Open Payments records show Martha R Wafer, M.D. received $574.41 in general payments during 2025 across 27 reported records.
Sumitomo Pharma America, Inc. accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $193.84 | 33.8% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.88 | 15.7% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $85.78 | 14.9% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $71.50 | 12.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.54 | 5.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.54 | 4.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.10 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.37 | 3.2% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $18.21 | 3.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.65 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $574.41 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $193.84 | 9 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $89.88 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $85.78 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $71.50 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.54 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 25 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 439 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 415 | 167 |
| Gabapentin | Gabapentin | 345 | 123 |
| Lisinopril | Lisinopril | 272 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 239 | 101 |
| Omeprazole | Omeprazole | 225 | 90 |
| Metformin Hcl | Metformin Hcl | 224 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 90 |
| Losartan Potassium | Losartan Potassium | 216 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 84 |
| Potassium Chloride | Potassium Chloride | 163 | 78 |
| Trazodone Hcl | Trazodone Hcl | 162 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 53 |
| Montelukast Sodium | Montelukast Sodium | 155 | 64 |
| Buprenorphine Hcl | Buprenorphine Hcl | 153 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 64 |
| Furosemide | Furosemide | 148 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 141 | 58 |
| Meloxicam | Meloxicam | 128 | 50 |
| Clonazepam | Clonazepam | 127 | 31 |
| Nifedipine Er | Nifedipine | 127 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 59 |
| Pregabalin | Pregabalin | 122 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 121 | 45 |
| Linzess | Linaclotide | 119 | 51 |
| Ozempic | Semaglutide | 116 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 50 |
| Metformin Hcl Er | Metformin Hcl | 103 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 25 |
| Ezetimibe | Ezetimibe | 102 | 49 |
| Methocarbamol | Methocarbamol | 101 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | 28 |
| Carvedilol | Carvedilol | 91 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 23 |
| Alprazolam | Alprazolam | 81 | 17 |
| Buspirone Hcl | Buspirone Hcl | 80 | 28 |
| Meclizine Hcl | Meclizine Hcl | 74 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 33 |
| Jardiance | Empagliflozin | 72 | 26 |
| Mirtazapine | Mirtazapine | 71 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 69 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 30 |
| Ibuprofen | Ibuprofen | 67 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 31 |
| Promethazine Hcl | Promethazine Hcl | 67 | 14 |
| Alendronate Sodium | Alendronate Sodium | 65 | 24 |
| Allopurinol | Allopurinol | 65 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 25 |
| Mounjaro | Tirzepatide | 59 | 15 |
| Simvastatin | Simvastatin | 58 | 30 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 55 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 23 |
| Glipizide | Glipizide | 53 | 21 |
| Bupropion Xl | Bupropion Hcl | 50 | 19 |
| Trulicity | Dulaglutide | 50 | 19 |
| Farxiga | Dapagliflozin Propanediol | 49 | 17 |
| Risperidone | Risperidone | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 21 |
| Myrbetriq | Mirabegron | 46 | 15 |
| Eliquis | Apixaban | 45 | 17 |
| Sulindac | Sulindac | 44 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 44 | 15 |
| Clonidine Hcl | Clonidine Hcl | 43 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 20 |
| Invega Sustenna | Paliperidone Palmitate | 42 | suppressed |
| Levetiracetam | Levetiracetam | 42 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 20 |
| Baclofen | Baclofen | 41 | 19 |
| Lidocaine | Lidocaine | 41 | 16 |
| Famotidine | Famotidine | 40 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 36 |
| Atenolol | Atenolol | 39 | 17 |
| Spironolactone | Spironolactone | 39 | 16 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 37 | 13 |
| Nabumetone | Nabumetone | 37 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 37 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | 14 |
| Diazepam | Diazepam | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 16 |
| Rybelsus | Semaglutide | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | 12 |
| Gemtesa | Vibegron | 29 | suppressed |
| Lactulose | Lactulose | 29 | 13 |
| Sertraline Hcl | Sertraline Hcl | 29 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | 11 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | 12 |
| Fenofibrate | Fenofibrate | 24 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | 11 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Topiramate | Topiramate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Soliris | Eculizumab | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | 11 |
| Ibu | Ibuprofen | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 13 |
| Nystatin | Nystatin | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Prednisone | Prednisone | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | 14 |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $574.41 · 27 records | Sumitomo Pharma America, Inc. | AIRSUPRA, AREXVY, BRIXADI, CAPLYTA, COBENFY, FANAPT, GEMTESA, IBSRELA, OTEZLA, REPATHA, SUBLOCADE, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error